Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.

Chromosomal abnormalities are present in most (if not all) patients with multiple myeloma (MM) and primary plasma cell leukemia (PCL). Furthermore, recent data have shown that numerical chromosomal changes are present in most individuals with monoclonal gammopathy of undetermined significance (MGUS). Epidemiological studies have shown that up to one third of MM may emerge from pre-existing MGUS. To clarify further possible stepwise chromosomal aberrations on a pathway between MGUS and MM, we have analyzed 158 patients with either MM or primary PCL and 19 individuals with MGUS using fluorescence in situ hybridization (FISH). Our FISH analyses were designed to detect illegitimate IGH rearrangements at 14q32 or monosomy 13. Whereas translocations involving the 14q32 region were observed with a similar incidence (60%) in both conditions, a significant difference was found in the incidence of monosomy 13 in MGUS versus MM or primary PCL. It was present in 40% of MM/PCL patients, but in only 4 of 19 MGUS individuals. Moreover, whereas monosomy 13 was found in the majority of plasma cells in MM, it was observed only in cell subpopulations in MGUS. It is noteworthy that, in a group of 20 patients with MM and a previous MGUS history, incidence of monosomy 13 was 70% versus 31% in MM patients without a known history of MGUS (P =.002). Thus, this study highlights monosomy 13 as correlated with the transformation of MGUS to overt MM and may define 2 groups of MM with possible different natural history and outcome, ie, post-MGUS MM with a very high incidence of monosomy 13 and de novo MM in which other genetic events might be involved. Serial analyses of individuals with MGUS will be needed to validate this model.

[1]  R. Bataille,et al.  High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization , 1999, Genes, chromosomes & cancer.

[2]  R. Bataille,et al.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. , 1998, Cancer research.

[3]  M. Batzer,et al.  Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia , 1998, Genes, chromosomes & cancer.

[4]  C. Bastard,et al.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases , 1998, Leukemia.

[5]  J. Miguel,et al.  Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. , 1998, Blood.

[6]  A. Glassman,et al.  Prognostic value of cytogenetics in multiple myeloma , 1998, British journal of haematology.

[7]  M. Rocchi,et al.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. , 1997, Blood.

[8]  F. Bauters,et al.  Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. , 1997, Blood.

[9]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[10]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[11]  J. Cigudosa,et al.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations , 1997, Genes, chromosomes & cancer.

[12]  P. L. Bergsagel,et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. Stevenson,et al.  Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. , 1996, Blood.

[14]  F. Bauters,et al.  Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. , 1995, Leukemia.

[15]  B. Barlogie,et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.

[16]  O. Haas,et al.  Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. , 1995, Blood.

[17]  U. Jäger,et al.  Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. , 1995, Cancer research.

[18]  T. Facon,et al.  Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells , 1995, British journal of haematology.

[19]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[20]  J. Mary,et al.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. , 1995, Blood.

[21]  M. Taniwaki,et al.  Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. , 1994, Blood.

[22]  W. O'Fallon,et al.  Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Hossfeld,et al.  Karyotype in multiple myeloma and plasma cell leukaemia. , 1993, European journal of cancer.

[24]  R A Kyle,et al.  "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.

[25]  B. Klein,et al.  In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma , 1991, European journal of immunology.

[26]  B. Barlogie,et al.  Plasma cell karyotype in multiple myeloma. , 1988, Blood.

[27]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.

[28]  R. Kyle,et al.  Smoldering multiple myeloma. , 1980, The New England journal of medicine.

[29]  R. Bataille,et al.  High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization , 1999, Genes, chromosomes & cancer.

[30]  R. Bataille,et al.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. , 1998, Cancer research.

[31]  M. Batzer,et al.  Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia , 1998, Genes, chromosomes & cancer.

[32]  C. Bastard,et al.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases , 1998, Leukemia.

[33]  J. Miguel,et al.  Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. , 1998, Blood.

[34]  M. Rocchi,et al.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. , 1997, Blood.

[35]  F. Bauters,et al.  Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. , 1997, Blood.

[36]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[37]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[38]  J. Cigudosa,et al.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations , 1997, Genes, chromosomes & cancer.

[39]  P. L. Bergsagel,et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  F. Stevenson,et al.  Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. , 1996, Blood.

[41]  F. Bauters,et al.  Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. , 1995, Leukemia.

[42]  B. Barlogie,et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.

[43]  O. Haas,et al.  Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. , 1995, Blood.

[44]  U. Jäger,et al.  Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. , 1995, Cancer research.

[45]  T. Facon,et al.  Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells , 1995, British journal of haematology.

[46]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[47]  J. Mary,et al.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. , 1995, Blood.

[48]  M. Taniwaki,et al.  Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. , 1994, Blood.

[49]  W. O'Fallon,et al.  Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  D. Hossfeld,et al.  Karyotype in multiple myeloma and plasma cell leukaemia. , 1993, European journal of cancer.

[51]  R A Kyle,et al.  "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.

[52]  B. Klein,et al.  In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma , 1991, European journal of immunology.

[53]  B. Barlogie,et al.  Plasma Cell Karyotype in Multiple Myeloma , 1988 .

[54]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.

[55]  R. Kyle,et al.  Smoldering multiple myeloma. , 1980, The New England journal of medicine.